COO Stock: +10% Revenue Growth but GLP-1 Still Haunts Diabetes Q2 FY2026

RBRK Stock: 4-for-1 Split + Record ARR Q1 FY2027

Rubrik, Inc. Q1 FY2027 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: BUY (4/5 conviction, STRONG) - CURRENT @ $80.00 - BUY - BUY below $65.00 with $55.00 stop - AVOID above $110.00 TRIGGER: ARR growth 35% next Q + GAAP profitability sustained WINDOW: 2 quarters TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 12 Strong Buy / 6 Buy / 8 Hold / 1 Sell / 1 Strong Sell - Buy - Median 12-month price target: $621.00 (range $368 - $775) - Charged Alpha vs consensus: SLIGHT DIVERGE THESIS CrowdStrike's Q1 FY2027 result is the definitive close of the outage-recovery chapter: record net new ARR at $256M plus thirty-two percent growth, a massive EPS beat, record FCF at $468M, and a stock split signal management's own confidence in the trajectory. Bull lever: Net new ARR accelerating to plus thirty-two percent YoY with enterprise gross retention at record highs proves the platform is sticky; the four-module-plus attach rate continues to expand, pulling higher-margin cloud and identity revenue that should push FCF margins toward forty percent by FY2029. Key risk: At $748 the stock trades twenty percent above Street median price target and at ninety-five times EV-FCF - the multiple requires flawless execution; a soft Q2 print or any macro-driven enterprise budget freeze would reset the multiple sharply given the premium embedded. QUALITY CHECK - Management quality grade: A (CEO George Kurtz navigated the July 2024 outage with transparency and speed; customer concessions preserved retention; Falcon Flex platform strategy is delivering record net new ARR; non-GAAP margins expanding materially in FY2027) - Earnings quality grade: B+ (Strong FCF generation and ARR compounding; watch the large GAAP/non-GAAP gap from SBC (~19% of revenue) and the Falcon Flex deferred recognition mechanics that can create revenue timing noise) CHAPTERS 0:00 Hook 0:30 S0b_Year 1:12 The Print 2:14 S1b_BeatDecomp 2:37 The Trend 3:20 The Segments 4:02 The FCF Bridge 4:47 S4b_MarginQual 5:31 Guidance & The Narrative Diff 6:23 S5b_Catalyst 6:45 Peer Dot-Plot 7:25 S6b_Valuation 8:05 Management & Earnings Quality 9:02 S8a_Call 9:39 S8b_Call KEY METRICS - Q1 FY2027 - Revenue: $0.39B (YoY +39.0%, beat est by +3.2%) - EPS: $-0.03 (vs $-0.03 est, beat +0.0%) - Operating margin: -18.0% - Free cash flow: $0.07B (19.0% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q4 FY2026 call, CEO Bipul Sinha said: 'We are seeing enterprises treat cyber resilience as a board-level mandate. Our pipeline has never been stronger, and we are winning competitive displacements at a record pace.'" - This call: "Bipul Sinha on the Q1 FY2027 call: 'This is the dawn of agentic cyber resilience. AI is not just changing how we build products - it is fundamentally reshaping how enterprises think about data protection, recovery, and continuity. Rubrik is the platform they turn to.'" - Tone shift: The combination of revenue acceleration, ARR compounding, positive FCF, and a full raise on guidance is exactly the beat-and-raise formula that institutional investors want from a Rule of 40 SaaS compounder. The agentic AI angle adds a new growth vector that was not in consensus models. DATA SOURCES - FMP (financialmodelingprep.com) - Rubrik, Inc. Q1 FY2027 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in RBRK. Do your own research before any investment decision. #RBRK #Rubrik,Inc. #earnings #investing #stocks #ChargedAlpha

DOCU Stock: AI Agreement Pivot Q1 FY2027

DocuSign, Inc. Q1 FY2027 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $68.50 - HOLD - BUY below $58.00 with $46.00 stop - AVOID above $98.00 TRIGGER: Two consecutive quarters of NRR back above 103% OR billings growth exceeding twelve percent - both signal IAM upsell is working and justify an upgrade WINDOW: 12-18 months - IAM adoption proof plus AI monetization curve TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 2 Strong Buy / 8 Buy / 16 Hold / 2 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $72.00 (range $55 - $95) - Charged Alpha vs consensus: Charged Alpha is in line with consensus at HOLD. THESIS DocuSign is the dominant agreement platform with eighty-one percent gross margins, twenty-seven percent FCF margin, and a credible IAM pivot adding AI intelligence to the agreement layer for two hundred fifty thousand enterprise customers. Bull lever: IAM upsell to the existing base is a multi-billion dollar TAM expansion; AI summarization and insights drive incremental ARPU without new customer acquisition cost; billings growing ahead of revenue is a leading indicator of re-acceleration. Key risk: Revenue growth is only nine percent with NRR near one hundred percent rather than expanding, signaling the base is not yet accelerating; IAM adoption is early and the timeline to meaningful revenue contribution is uncertain. QUALITY CHECK - Management quality grade: B (CEO Allan Thygesen, appointed 2022, has stabilized DocuSign after post-COVID turbulence, returned the company to GAAP profitability, launched the IAM platform pivot, and maintained strong FCF generation. Capital allocation improved with buybacks; SBC declined as a percent of revenue.) - Earnings quality grade: B+ (Subscription dominance at ninety-seven percent of revenue, eighty-one percent gross margins, and twenty-seven percent FCF margin are high quality. GAAP profitability is modest but stable. SBC is declining as a percentage. No material one-time items.) CHAPTERS 0:00 Hook 0:12 S0b_Year 0:45 The Print 1:42 S1b_BeatDecomp 2:21 The Trend 3:10 The Segments 3:59 The FCF Bridge 4:46 S4b_MarginQual 5:18 Guidance & The Narrative Diff 6:05 S5b_Catalyst 6:51 Peer Dot-Plot 7:38 S6b_Valuation 8:22 Management & Earnings Quality 9:25 S8a_Call 10:12 S8b_Call KEY METRICS - Q1 FY2027 - Revenue: $0.83B (YoY +9.0%, beat est by +0.7%) - EPS: $1.03 (vs $1.00 est, beat +3.0%) - Operating margin: 2.8% - Free cash flow: $0.22B (27.0% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "Last quarter CEO Allan Thygesen said DocuSign was in the early stages of a multi-year transformation from e-signature leader to Intelligent Agreement Management platform." - This call: "We are executing on IAM and seeing customers expand from signature into agreement intelligence, with AI summarization and insights driving new use cases and incremental ARPU that did not exist two years ago." - Tone shift: Small but clean beat with guidance raised; the IAM pivot narrative now has tangible product evidence with AI features in market; the re-acceleration thesis is early but building DATA SOURCES - FMP (financialmodelingprep.com) - DocuSign, Inc. Q1 FY2027 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in DOCU. Do your own research before any investment decision. #DOCU #DocuSign,Inc. #earnings #investing #stocks #ChargedAlpha

CAL Stock: EPS Beat Revenue Missed Q1 FY2027

Caleres, Inc. Q1 FY2027 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $18.50 - HOLD - BUY below $16.00 with $12.00 stop - AVOID above $26.00 TRIGGER: Famous Footwear comp re-acceleration above +2% for two consecutive quarters; or Brand Portfolio gross margin recovery above 45% WINDOW: Through Q2 FY2027 earnings (September 2026) TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 0 Strong Buy / 3 Buy / 7 Hold / 1 Sell / 0 Strong Sell - HOLD - Median 12-month price target: $24.00 (range $16 - $30) - Charged Alpha vs consensus: IN LINE THESIS Caleres operates two complementary footwear businesses: Famous Footwear (retail, ~860 stores, value-positioned) and Brand Portfolio (wholesale + DTC for Sam Edelman, Naturalizer, Allen Edmonds, Vince, Dr. Scholl's). The Q1 beat shows both segments are stabilizing after two challenging quarters. Bull lever: Famous Footwear's Famously You loyalty program at 30M+ members drives repeat traffic and customer lifetime value. If comps accelerate to +2%+, operating leverage on the fixed-cost retail footprint could meaningfully expand margins. Key risk: Brand Portfolio's heavy reliance on Asian-sourced imported footwear creates tariff vulnerability. A 10-15% tariff escalation could compress gross margins by 150-200bps without the ability to fully pass through to wholesale customers. QUALITY CHECK - Management quality grade: B (CEO Jay Schmidt has steadied Caleres after the COVID disruption and managed a disciplined store portfolio at Famous Footwear. Brand Portfolio expansion via Sam Edelman and Naturalizer DTC shows strategic intent, but execution against tariff headwinds and a cautious consumer has been mixed.) - Earnings quality grade: B (GAAP EPS of $0.38 essentially matches adjusted EPS with minimal add-backs. Balance sheet carries ~$420M debt (majority operating leases for 860-store fleet). Financial debt approximately $200M. Cash approximately $60M. Inventory discipline maintained.) CHAPTERS 0:00 Hook 0:14 S0b_Year 0:56 The Print 2:10 S1b_BeatDecomp 2:26 The Trend 3:35 The Segments 4:26 The FCF Bridge 5:28 S4b_MarginQual 6:10 Guidance & The Narrative Diff 7:12 S5b_Catalyst 7:49 Peer Dot-Plot 8:28 S6b_Valuation 9:11 Management & Earnings Quality 10:21 S8a_Call 11:00 S8b_Call KEY METRICS - Q1 FY2027 - Revenue: $0.67B (YoY -1.2%, beat est by +0.6%) - EPS: $0.38 (vs $0.37 est, beat +2.7%) - Operating margin: 3.8% - Free cash flow: $0.01B (2.2% margin) NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q4 FY2026 call, CEO Jay Schmidt highlighted investment in the Famously You loyalty program and ongoing brand differentiation as the levers for Famous Footwear traffic recovery." - This call: "We are encouraged by the positive comparable sales in Famous Footwear and sequential gross margin improvement in Brand Portfolio as we navigate a dynamic tariff environment." - Tone shift: Caleres outperformed modestly on both lines. Famous Footwear comps inflected positive, a bullish signal. Brand Portfolio recovered sequentially. The year-over-year revenue decline (-1.2%) and slight gross margin compression (-30bps) remain as mild overhangs. DATA SOURCES - FMP (financialmodelingprep.com) - Caleres, Inc. Q1 FY2027 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in CAL. Do your own research before any investment decision. #CAL #Caleres,Inc. #earnings #investing #stocks #ChargedAlpha

GWRE Stock: +16% Rev Beat Q1 FY2027

Guidewire Software Q3 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: BUY (4/5 conviction, STRONG) - CURRENT @ $215.00 - BUY - BUY below $180.00 with $175.00 stop - AVOID above $290.00 TRIGGER: Q4 FY26 ARR ending at $1.22B+ AND FY27 guidance implying ARR acceleration to twenty-plus percent growth WINDOW: 18-24 months - Cloud Platform mid-cycle inflection delivering margin expansion and ARR compounding TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 10 Strong Buy / 12 Buy / 8 Hold / 1 Sell / 0 Strong Sell - BUY - Median 12-month price target: $240.00 (range $185 - $290) - Charged Alpha vs consensus: Charged Alpha aligns with Street consensus - BUY with strong conviction, buy below $230. THESIS Guidewire is the only cloud-native core system platform for P&C insurance at scale - regulatory-grade workflows, near-zero churn, and a migration cycle with seven to ten years remaining. Bull lever: ARR compounds to $2B by FY2029 at twenty percent growth; margins expand to thirty percent; stock re-rates to fifteen-plus times forward revenue - potential sixty to eighty percent upside from current levels. Key risk: Multiple compression if ARR growth slips below fifteen percent; implementation cycle risk from carrier IT budget cuts in macro downturn. QUALITY CHECK - Management quality grade: A (Mike Rosenbaum - CEO since 2019, led company through on-premise to cloud transition; execution track record strong with consistent beat-and-raise; insider ownership meaningful) - Earnings quality grade: A- (Non-GAAP EPS beat is clean and large; ARR growth is real recurring revenue; FCF conversion at twenty-seven percent is healthy; SBC at thirteen percent of revenue is moderate for SaaS) CHAPTERS 0:00 Hook 0:12 S0b_Year 0:48 The Print 1:42 S1b_BeatDecomp 2:27 The Trend 3:01 The Segments 3:59 The FCF Bridge 4:39 S4b_MarginQual 5:17 Guidance & The Narrative Diff 6:20 S5b_Catalyst 6:54 Peer Dot-Plot 7:32 S6b_Valuation 8:03 Management & Earnings Quality 8:48 S8a_Call 9:29 S8b_Call KEY METRICS - Q3 FY2026 - Revenue: $0.37B (YoY +27.0%, beat est by +4.6%) - EPS: $1.22 (vs $0.74 est, beat +64.9%) - Operating margin: 19.5% - Free cash flow: $0.10B (27.4% margin) Guidewire delivered its best quarter in years - revenue up twenty-seven percent to $372.5M, ARR crossing $1.147B at nineteen percent growth, and non-GAAP EPS of $1.22 nearly doubling the $0.74 estimate. The cloud migration inflection thesis is no longer narrative; it is now a measurable acceleration in every metric. CEO Mike Rosenbaum's steady hand through the on-premise to cloud transition is being validated. At fourteen-point-five times forward EV/Sales the stock prices in execution risk but not premium - with ARR compounding to two billion by late decade and margins expanding toward thirty percent, the BUY case is compelling at current levels below $230. NARRATIVE DIFF - what changed in management tone - Prior call: "Last quarter Mike Rosenbaum said Guidewire was making steady progress on Cloud Platform migrations, with ARR growing in the mid-teens and new insurance carrier logos continuing to sign." - This call: "We are seeing real acceleration in cloud adoption. More carriers are migrating faster than expected, and the Guidewire Cloud Platform is becoming the de facto standard for property and casualty insurance technology." - Tone shift: ARR growth re-accelerated from mid-teens to nineteen percent, subscription revenue jumped to thirty-two percent YoY, and margin expanded to nineteen-point-five percent - all three vectors beat simultaneously for the first time in multiple quarters DATA SOURCES - FMP (financialmodelingprep.com) - Guidewire Software Q3 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in GWRE. Do your own research before any investment decision. #GWRE #GuidewireSoftware #earnings #investing #stocks #ChargedAlpha

COO Stock: +10% Revenue Growth but GLP-1 Still Haunts Diabetes Q2 FY2026

The Cooper Companies, Inc. Q2 FY2026 earnings breakdown - conversational walkthrough with a price-aware verdict and Wall Street consensus comparison. THE CALL: HOLD (3/5 conviction, MODERATE) - CURRENT @ $62.13 - HOLD - BUY below $52.00 with $48.00 stop - AVOID above $90.00 TRIGGER: A confirmed CooperSurgical divestiture at a clean price is the bull catalyst that could re-rate the stock to the $75-85 range WINDOW: 12-18 months -- CooperSurgical resolution and continued MiSight ramp are the key value drivers TRACKER: chargedalpha.com WALL STREET CONSENSUS - Ratings: 8 Strong Buy / 6 Buy / 4 Hold / 0 Sell / 0 Strong Sell - BUY - Median 12-month price target: $80.00 (range $61 - $101) - Charged Alpha vs consensus: ALIGN THESIS Cooper Companies is a best-in-class contact lens franchise with a 10-streak beat record at a 38% discount to 52-week highs. The HOLD thesis: accumulate toward the $58 add-zone, wait for CooperSurgical strategic review resolution, and own the re-rating when the lens franchise trades at a pure-play multiple. Bull lever: MiSight myopia management TAM expansion across Asia and Europe (24% growth, $32M now, $500M+ addressable), MyDay double-digit growth reinforcing daily silicone hydrogel dominance, and a clean CooperSurgical divestiture at fair value -- combined could drive 30-50% upside from current levels. Key risk: CooperSurgical strategic review fails to attract a buyer at an acceptable price; Asia Pacific contact lens market softens further; tariff and freight costs compress Q3 gross margin more than the guided 66% floor; GAAP EPS losses extend if additional litigation charges emerge. QUALITY CHECK - Management quality grade: A- (Ten consecutive quarters beating consensus; FY2026 guidance raised; reorganization synergies driving 260bps non-GAAP operating margin expansion; CooperSurgical strategic review demonstrates portfolio optimization discipline) - Earnings quality grade: A- (Non-GAAP operating margin 27% with consistent organic revenue growth; GAAP-to-non-GAAP gap is a one-time litigation charge not operational; FCF generation constructive at $96M quarterly with annual guidance of $650M) CHAPTERS 0:00 Hook 0:31 S0b_Year 1:12 The Print 1:57 S1b_BeatDecomp 2:21 The Trend 3:08 The Segments 4:09 The FCF Bridge 4:52 S4b_MarginQual 5:42 Guidance & The Narrative Diff 6:31 S5b_Catalyst 7:08 Peer Dot-Plot 7:53 S6b_Valuation 8:35 Management & Earnings Quality 9:37 S8a_Call 10:02 S8b_Call KEY METRICS - Q2 FY2026 - Revenue: $1.08B (YoY +8.0%, beat est by +2.6%) - EPS: $1.21 (vs $1.10 est, beat +10.0%) - Operating margin: 27.0% - Free cash flow: $0.10B (8.9% margin) Cooper Companies Q2 FY2026 is a clean beat-and-raise on the metrics that matter. The contact lens business is winning -- MyDay daily silicone hydrogel growing double digits, MiSight pediatric myopia control up 24% to $32 million with Japan and Europe exceeding expectations, and the tenth consecutive quarter of beating consensus EPS. The GAAP EPS is negative due to the CooperSurgical litigation settlement, but that is a one-time item with 95% of claims resolved. The strategic review of CooperSurgical is the real story: if management executes a clean divestiture, COO becomes a pure-play premium contact lens company -- a business that could command 18-20x earnings versus today's 13.5x. At $62, down 38% from the 52-week high, the risk-reward is improving. HOLD with an eye toward adding below $58. NARRATIVE DIFF - what changed in management tone - Prior call: "On the Q1 FY2026 call, CEO Albert White highlighted CooperVision organic growth of 3% slightly below expectations due to Asia Pacific weakness and signaled the strategic review of CooperSurgical was in early stages." - This call: "Q2 FY2026 marks CooperVision's acceleration to 4% organic growth with MiSight's 24% ramp leading the way; CooperSurgical strategic review shows robust buyer interest with over 95% of litigation claims settled." - Tone shift: The core lens business is on track and executing; the remaining uncertainty is CooperSurgical exit pricing and timing DATA SOURCES - FMP (financialmodelingprep.com) - The Cooper Companies, Inc. Q2 FY2026 press release + earnings call DISCLAIMER This is for informational and educational purposes only. Not financial advice. Charged Alpha does not have a position in COO. Do your own research before any investment decision. #COO #TheCooperCompanies,Inc. #earnings #investing #stocks #ChargedAlpha